HISTORIC MOU SIGNED FOR MAJOR NEW RESEARCH PROGRAM FOR CANNABIS-BASED MEDICINES FOR PAEDIATRIC EPILEPSY
Member for Coffs Harbour, Andrew Fraser, has welcomed the NSW Government’s announcement that a Memorandum of Understanding (MOU) has been signed with GW Pharmaceuticals (GW) to progress a major new research program for cannabis-based medicines in children with severe, drug resistant paediatric epilepsy.
Mr Fraser said many children are suffering and this announcement provides hope for families.
“This is great news for the Stevens family of Coffs Harbour. Nine year old Deisha suffers from epilepsy and has found relief through the use of a cannabis product. Sadly, Deisha’s father, David, who was a strong advocate for the use of medicinal cannabis, passed away in June this year.
“This is a Government showing incredible progress, NSW is the first state in Australia to provide legal and safe access to cannabis-based medicines for children suffering from drug resistant epilepsy,” Mr Fraser said.
The MOU will facilitate:
- A world first, phase 2 clinical trial in children for GW’s novel product containing the cannabinoid cannibidivarin (CBDV)
- A compassionate access scheme for EpidiolexÒ, GW’s product containing cannabidiol (CBD) which is currently in late stage trials in paediatric epilepsy in the United States
- Provision for NSW to host additional Phase 3 clinical trials of EpidiolexÒ in children with treatment-resistant epilepsy
- A phase 4 clinical trial of EpidiolexÒ based on phase 3 studies
The MOU, between the NSW Government and GW Pharmaceuticals, comes as part of the NSW Government’s $21 million commitment to support clinical trials and establish the NSW Centre for Medicinal Cannabis Research and Innovation.
More information about medicinal cannabis in NSW is available at www.health.nsw.gov.au/cannabis.
Specific information regarding trials email email@example.com or call the Cannabis Trials Help Line on 1800 217 257.
29 October 2015
For media comment contact Andrew Fraser on 6652 6500.